ATE555788T1 - Verfahren zur behandlung neurologischer erkrankungen mittels verstärkung der beta - glucocerebrosidaseaktivität - Google Patents

Verfahren zur behandlung neurologischer erkrankungen mittels verstärkung der beta - glucocerebrosidaseaktivität

Info

Publication number
ATE555788T1
ATE555788T1 AT07812295T AT07812295T ATE555788T1 AT E555788 T1 ATE555788 T1 AT E555788T1 AT 07812295 T AT07812295 T AT 07812295T AT 07812295 T AT07812295 T AT 07812295T AT E555788 T1 ATE555788 T1 AT E555788T1
Authority
AT
Austria
Prior art keywords
glucocerebrosidase
enhancement
beta
neurological diseases
treating neurological
Prior art date
Application number
AT07812295T
Other languages
English (en)
Inventor
Brandon Wustman
Original Assignee
Amicus Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38834440&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE555788(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amicus Therapeutics Inc filed Critical Amicus Therapeutics Inc
Application granted granted Critical
Publication of ATE555788T1 publication Critical patent/ATE555788T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Hydrogenated Pyridines (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT07812295T 2006-06-23 2007-06-25 Verfahren zur behandlung neurologischer erkrankungen mittels verstärkung der beta - glucocerebrosidaseaktivität ATE555788T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81595206P 2006-06-23 2006-06-23
PCT/US2007/072016 WO2007150064A2 (en) 2006-06-23 2007-06-25 METHOD FOR THE TREATMENT OF NEUROLOGICAL DISORDERS BY ENHANCING THE ACTIVITY OF β-GLUCOCEREBROSIDASE

Publications (1)

Publication Number Publication Date
ATE555788T1 true ATE555788T1 (de) 2012-05-15

Family

ID=38834440

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07812295T ATE555788T1 (de) 2006-06-23 2007-06-25 Verfahren zur behandlung neurologischer erkrankungen mittels verstärkung der beta - glucocerebrosidaseaktivität

Country Status (15)

Country Link
US (4) US7829579B2 (de)
EP (1) EP2040548B1 (de)
JP (1) JP5303458B2 (de)
KR (1) KR101402554B1 (de)
AT (1) ATE555788T1 (de)
AU (1) AU2007260812B2 (de)
BR (1) BRPI0713442A2 (de)
CA (1) CA2656643C (de)
DK (1) DK2040548T3 (de)
ES (1) ES2387845T3 (de)
IL (1) IL196151A (de)
MX (1) MX2009000032A (de)
PT (1) PT2040548E (de)
WO (1) WO2007150064A2 (de)
ZA (1) ZA200900270B (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7138262B1 (en) 2000-08-18 2006-11-21 Shire Human Genetic Therapies, Inc. High mannose proteins and methods of making high mannose proteins
PT2040548E (pt) 2006-06-23 2012-08-02 Amicus Therapeutics Inc Método para o tratamento de distúrbios neurológicos através do aumento da atividade da -glucocerebrosidase
GB0622702D0 (en) * 2006-11-15 2006-12-27 Univ Dundee Selective glycosidase inhibitors
EP2154969B1 (de) * 2007-05-16 2015-11-18 The Brigham and Women's Hospital, Inc. Behandlung von synukleinopathien
EP2659904B1 (de) * 2008-06-26 2015-09-16 Orphazyme APS Verwendung von Hsp70 als Regler der enzymatischen Aktivität
BRPI0920498A2 (pt) * 2008-11-14 2019-09-24 Neuraltus Pharmaceuticals Inc método de tratamento de uma condição em um sujeito
ES2564093T3 (es) * 2009-04-09 2016-03-17 Amicus Therapeutics, Inc. Métodos para prevenir y/o tratar trastornos del almacenamiento lisosomal
BRPI1015472A2 (pt) * 2009-04-09 2015-11-24 Amicus Therapeutics Inc métodos para prevenção e/ou tratamento de doenças degenerativas do sistema nervoso central
GB0906159D0 (en) * 2009-04-09 2009-05-20 Summit Corp Plc Drug combination for the treatment of proteostatic diseases
US20110070643A1 (en) * 2009-05-26 2011-03-24 Do Hung V Utilization of Pharmacological Chaperones to Improve Manufacturing and Purification of Biologics
US9206457B2 (en) * 2009-05-26 2015-12-08 Amicus Therapeutics, Inc. Utilization of pharmacological chaperones to improve manufacturing and purification of biologics
CN105126086B (zh) * 2009-07-28 2019-05-14 夏尔人类遗传性治疗公司 用于治疗戈谢病的组合物和方法
RS55679B1 (sr) * 2009-10-19 2017-07-31 Amicus Therapeutics Inc Nove smeše za sprečavanje i/ili lečenje degenerativnih poremećaja centralnog nervnog sistema
PT2490712E (pt) 2009-10-19 2015-10-27 Amicus Therapeutics Inc Método para tratar a doença de alzheimer utilizando chaperones farmacológicos para aumentar a atividade de gangliosidases
AU2010308397B2 (en) 2009-10-19 2016-04-07 Amicus Therapeutics, Inc. Novel compositions for preventing and/or treating lysosomal storage disorders
EP3626255A1 (de) 2010-11-30 2020-03-25 Orphazyme A/S Procédés pour accroître l'activité cellulaire de hsp70
EP3552664A1 (de) 2011-05-12 2019-10-16 Proteostasis Therapeutics, Inc. Proteostase-regulatoren
EP2533051A1 (de) 2011-06-06 2012-12-12 Centogene GmbH Verfahren zur Diagnose von Morbus Gaucher
JP6061922B2 (ja) * 2011-06-22 2017-01-18 ザ ジェネラル ホスピタル コーポレイション プロテイノパチーの処置方法
JP2015504919A (ja) 2012-01-25 2015-02-16 プロテオステイシス セラピューティクス，インコーポレイテッド プロテアソーム活性を調節する化合物
SG11201502989XA (en) * 2012-11-05 2015-05-28 Genzyme Corp Compositions and methods for treating proteinopathies
US9750712B2 (en) 2012-12-07 2017-09-05 Rush University Medical Center Composition and method for treating neuronal ceroid lipofuscinosis
EP3087056A4 (de) 2013-12-23 2017-07-19 Alectos Therapeutics Inc. Glucocerebrosidasemodulatoren und verwendungen davon
US9675627B2 (en) 2014-04-14 2017-06-13 Amicus Therapeutics, Inc. Dosing regimens for treating and/or preventing cerebral amyloidoses
PL3193840T3 (pl) 2014-09-15 2021-12-06 Orphazyme A/S Preparat arimoklomolu
MX2017005940A (es) 2014-11-06 2018-01-11 Lysosomal Therapeutics Inc Pyrazolo [1, 5-a] pirimidinas sustituidas y su uso en el tratamiento de trastornos médicos.
AU2016256895B2 (en) 2015-05-07 2022-05-26 Takeda Pharmaceutical Company Limited Glucocerebrosidase gene therapy for parkinson's disease
EP3440081A4 (de) * 2016-04-06 2019-09-18 Lysosomal Therapeutics Inc. Pyrrolo[1,2-a]pyrimidinyl-carboxamid-verbindungen und deren verwendung in der behandlung von medizinischen störungen
KR20180133461A (ko) 2016-04-06 2018-12-14 리소소말 테라퓨틱스 인크. 피라졸로[1,5-a]피리미디닐 카르복스아미드 화합물 및 의학적 장애의 치료에서의 그의 용도
CA3020305A1 (en) 2016-04-06 2017-10-12 Lysosomal Therapeutics Inc. Imidazo [1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders
EP3442530A1 (de) 2016-04-13 2019-02-20 Orphazyme A/S Hitzeschockproteinen und cholesterinhomöostase
ES2831764T3 (es) 2016-04-29 2021-06-09 Orphazyme As Arimoclomol para el tratamiento de trastornos asociados a glucocerebrosidasa
JP7164774B2 (ja) 2016-05-05 2022-11-02 ビアル－アール・アンド・ディ・インベストメンツ・ソシエダーデ・アノニマ 置換イミダゾ［１，２－ｂ］ピリダジン、置換イミダゾ［１，５－ｂ］ピリダジン、関連化合物、および医学的障害の治療におけるその使用
EP3264092A1 (de) * 2016-07-01 2018-01-03 Centogene AG Verwendung von lyso-gb1 als krankheitsassoziiertes ziel
CA3078463A1 (en) * 2017-10-26 2019-05-02 Shire Human Genetic Therapies, Inc. Formulations comprising glucocerebrosidase and isofagomine
CN108428452B (zh) 2018-03-14 2019-12-13 百度在线网络技术（北京）有限公司 终端支架和远场语音交互系统
JP2021530465A (ja) 2018-06-27 2021-11-11 プロテオステイシス セラピューティクス， インコーポレイテッド プロテアソーム活性増強化合物
CA3103954A1 (en) 2018-06-27 2020-01-02 Proteostasis Therapeutics, Inc. Proteasome activity enhancing compounds
WO2020023390A1 (en) 2018-07-25 2020-01-30 Modernatx, Inc. Mrna based enzyme replacement therapy combined with a pharmacological chaperone for the treatment of lysosomal storage disorders
CN111450306B (zh) * 2020-03-06 2021-11-19 大连理工大学 外用纳米羟基磷灰石/聚多巴胺湿黏附型止血粉及其制备方法
KR20230128462A (ko) 2020-11-19 2023-09-05 제브라 덴마크 에이/에스 아리모클로몰 시트레이트 및 이의 중간체를 제조하기 위한 공정

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE272842T1 (de) * 1996-10-15 2004-08-15 D Gen Ltd Diagnose spongiformer encephalopathie
GB2333362B (en) 1996-10-15 2001-05-16 Imperial College Typing and diagnosis of spongiform encephalopathy
US6274597B1 (en) * 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A
EP2857036B1 (de) 2003-01-31 2016-12-21 Mount Sinai School of Medicine of New York University Kombinationstherapie zur behandlung von proteinmangelstörungen
CN1901907A (zh) 2003-11-12 2007-01-24 阿米库斯治疗学公司 用于治疗戈谢病的葡糖并咪唑和多羟基环己烯基胺衍生物
EP1888068B1 (de) 2005-06-08 2014-05-21 Amicus Therapeutics, Inc. Behandlung von zns-erkrankungen in zusammenhang mit mutationen bei für lysosomale enzyme kodierenden genen
US7501439B2 (en) * 2006-05-24 2009-03-10 Amicus Therapeutics, Inc. Tartrate salt of isofagomine and methods of use
PT2040548E (pt) 2006-06-23 2012-08-02 Amicus Therapeutics Inc Método para o tratamento de distúrbios neurológicos através do aumento da atividade da -glucocerebrosidase
SG183747A1 (en) 2007-05-22 2012-09-27 Amicus Therapeutics Inc New method for preparing isofagomine and its derivatives

Also Published As

Publication number Publication date
EP2040548B1 (de) 2012-05-02
IL196151A0 (en) 2009-11-18
ZA200900270B (en) 2011-02-23
AU2007260812A1 (en) 2007-12-27
ES2387845T3 (es) 2012-10-02
KR20090021393A (ko) 2009-03-03
JP5303458B2 (ja) 2013-10-02
IL196151A (en) 2015-08-31
US9402837B2 (en) 2016-08-02
KR101402554B1 (ko) 2014-06-19
US20110052613A1 (en) 2011-03-03
US7829579B2 (en) 2010-11-09
DK2040548T3 (da) 2012-08-13
US20080009516A1 (en) 2008-01-10
EP2040548A4 (de) 2009-12-23
CA2656643A1 (en) 2007-12-27
AU2007260812B2 (en) 2012-08-16
CA2656643C (en) 2015-08-25
MX2009000032A (es) 2009-01-23
WO2007150064A2 (en) 2007-12-27
EP2040548A2 (de) 2009-04-01
US9119845B2 (en) 2015-09-01
US20170027919A1 (en) 2017-02-02
BRPI0713442A2 (pt) 2012-03-06
JP2009541489A (ja) 2009-11-26
WO2007150064A3 (en) 2008-02-21
US10064851B2 (en) 2018-09-04
US20150025109A1 (en) 2015-01-22
PT2040548E (pt) 2012-08-02

Similar Documents

Publication Publication Date Title
ATE555788T1 (de) Verfahren zur behandlung neurologischer erkrankungen mittels verstärkung der beta - glucocerebrosidaseaktivität
ATE516353T1 (de) Verwendung von rnai mit inhibierender parp aktivität zur herstelllung eines arzneimittels zur behandlung von krebs
MX2010004074A (es) Combinacion 059.
CY1108927T1 (el) Αναστολεις μιτωτικης κινεσινης
MX2021012126A (es) Composiciones y métodos para inhibir la expresión génica en el sistema nervioso central.
MX366774B (es) Uso de oligonucleótidos antisentido en la inhibición de transcrito antisentido natural para sirtuina 1.
ECSP066362A (es) Inhibidores de quinesina mitótica.
EA201591281A1 (ru) Рибонуклеиновые кислоты с 4'-тиомодифицированными нуклеотидами и связанные с ними способы
BR112013020041A2 (pt) compostos e métodos para a modulação de quinases, e indicações para os mesmos
MX2021012184A (es) Terapias genicas para trastornos lisosomales.
ATE446094T1 (de) Mitotische kinesin-hemmer
MX2010004614A (es) Composiciones para tratamiento del mal de parkinson.
EA201100150A1 (ru) Лечение аутоиммунного и воспалительного заболевания
WO2010040112A3 (en) Treatment of apolipoprotein-a1 related diseases by inhibition of natural antisense transcript to apolipoprotein-a1
DE60324449D1 (de) Inhibitoren der phosphodiesterase der zyklischen n, und deren verwendung in therapie
GT200500215A (es) Amidas sustituidas de àcido tienopirrolcarboxìlico, amidas del àcido pirrolotiazolcarboxìlico y anàlogos relacionados como inhibidores de la epsilon caseìna quinasa i
WO2009068659A3 (en) Novel disease treatment by predicting drug association
Wu et al. Pressure and inflammatory stimulation induced increase of cadherin-11 is mediated by PI3K/Akt pathway in synovial fibroblasts from temporomandibular joint
MX2013011996A (es) Metodos para regular la expresion de genes de sirtuina.
Lim et al. Endogenous stem cells in homeostasis and aging
WO2010065536A3 (en) Recombinant bone marrow stromal antigen-2 in the treatment of autoimmune diseases
MX2023001562A (es) Terapias genicas para trastornos lisosomales.
ATE529514T1 (de) Sirna zur hemmung der il-6-expression und diese enthaltende zusammensetzung
ATE554069T1 (de) Verwendung von tetrahydropyridinen zur behandlung von erkrankungen des zentralnervensystems
EA202192739A1 (ru) Генная терапия лизосомальных нарушений